🚀 Pharmidex In Silico Drug Discovery – Step 4: Molecular Docking! 🔬💻
February 26, 2025

Pharmidex continues advancing computational drug discovery! After identifying active/binding sites, our Molecular Docking step ensures precise interaction analysis between potential drug candidates and target proteins, streamlining lead optimization.


✨ Why is this step key?

✅ Predicts binding affinity and stability of drug candidates

✅ AI-enhanced docking for high-precision molecular interactions

✅ Accelerates hit-to-lead identification with accurate simulations

✅ Seamlessly integrates with the next in silico pipeline steps


By combining cutting-edge modeling and expert-driven analysis, we de-risk drug development and fast-track novel therapeutic discoveries.


📽️ Watch our latest video (3/5) showcasing how we refine drug-target interactions through Molecular Docking!


📩 Let’s collaborate to transform drug discovery!


#DrugDiscovery #Pharmidex #AIinBiotech #MolecularDocking #PharmaceuticalInnovation

Ash Alavijeh will be attending the Life Sciences Wallonia Business Forum

October 28, 2025
Pharmidex is pleased to share that Ash Alavijeh , our Head of Operations, will be attending the Life Sciences Wallonia Business Forum this evening at the Residence of the Belgian Ambassador. Hosted by the Economic Counsellor of Belgium-Wallonia Investment & Trade, the event brings together leading organisations across the European life sciences sector to explore how Wallonia supports international growth both financially and strategically. We look forward to connecting with international partners and exploring opportunities for collaboration and innovation in the European life sciences ecosystem.

Pharmidex is proud to sponsor the SMR meeting Target Identification and Validation in Drug Discovery

October 23, 2025
We’re excited that Janette Dalay Robertson (Business Development Manager) and Ian Knowles (Head of Respiratory) will attend, eager to meet attendees, share ideas and explore new collaborations to advance drug discovery and development. At Pharmidex , we know robust target validation is key to successful therapeutics. Our expertise in biomarker analysis, histology, in vivo models, and autoimmune disease research supports innovation across translational medicine.

We present our poster with VasoDynamics at Scotland’s Health R&I Conference

October 22, 2025
Pharmidex is delighted to announce our joint poster with VasoDynamics Ltd at Scotland’s Health Research and Innovation Conference on October 23rd in Edinburgh! We’re proud to be part of this inspiring event, organised by NHS Scotland and CSO Scotland , which brings together the brightest minds driving progress in health research, innovation, and life sciences. 📍 Visit our stand to learn more about our collaborative work. A printout of the poster will be available. Mo Alavijeh (FRSC, FRSM ) is looking forward to meeting attendees and discussing new opportunities for partnership and discovery. Together with VasoDynamics Ltd , we’re advancing science through collaboration and innovation. 🔗 Learn more about Pharmidex : www.pharmidex.com
More Posts